All News
Boers et al. GLORIA trial of long term 5mg pred in RA. Titled as "favourable balance of benefit and harm". I cannot agree. 24% increase adverse events, NNH 9, for DAS28 0.37 better at 1 year, and really no difference after that. @RheumNow #EULAR2022 OP0263 https://t.co/eO4f1CjH5q https://t.co/VyyZm1QvYy
Links:
Richard Conway RichardPAConway ( View Tweet)
Meudec et al. Comparative effects of JAKi on NK cell function on cancer cells (lymphoma and lung cancer). Tofacitinib had most negative impact. Interesting given blanket black box based on tofa data! @RheumNow #EULAR2022 OP0265 https://t.co/XSE7hP60Ui https://t.co/MjtAJcvWAD
Links:
Richard Conway RichardPAConway ( View Tweet)
Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI.
Early changes in PsO may suggest a PsA-like MRI pattern may be present!
Is this how we predict which PsO -> PsA?
@RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM
Robert B Chao, MD doctorRBC ( View Tweet)
Nyam et al. JAK-pot study. >90000 treatment courses. No difference in aHR for treatment stop due to adverse events in JAKi vs TNFi or non-TNF bDMARD. @RheumNow #EULAR2022 OP0266 https://t.co/3tgADvH1Bq https://t.co/2qLRzfMB9c
Links:
Richard Conway RichardPAConway ( View Tweet)
Zabotti et al. IL23i guselkumab. Machine learning identified clusters of MDA response @RheumNow #EULAR2022 OP0259 https://t.co/67tfuADxLs https://t.co/33Y5m37K3y
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 POS0278:
Proof of concept US study:
💎CPP crystals do NOT generate posterior shadowing
💎MSU and hydroxyapatite did have shadowing, proportional to concentration of crystals
@Rheumnow @MymaAlbaydaMD @USSONAR_Rh
Eric Dein ericdeinmd ( View Tweet)
There's nothing like a good physical examination
Temporal artery exam & ultrasound vs temporal artery biopsy
n=97 consecutive ?GCA pts from Carlo Salvarini's group
Very decent PPV
Those TA exam findings can be hard to find, but they're gold dust.
POS0820 #EULAR2022 @RheumNow https://t.co/X9TzIqQBaB
David Liew drdavidliew ( View Tweet)
#EULAR2022 POS0213
Beware of paradoxical low lipids in RA!
⭐️ETN+MTX vs MTX T2T:
Early ETN: increased in HLD, lesser LDL, differs from MTX. Correlates with clinical disease activity
@RheumNow https://t.co/c6GXadVwYN
Eric Dein ericdeinmd ( View Tweet)
SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Patel @NaomiRheumMD et al. Avacopan in AAV at different thresholds toxicity. Minimum clinically important difference for GTI is 10 points. Avacopan assoc lower glucocorticoid toxicity irrespective of threshold used. @RheumNow #EULAR2022 POS0833 https://t.co/8iIIAsMOlI
Richard Conway RichardPAConway ( View Tweet)
Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bisphosphonate in bone group 60% vs 6%. Better response to DMARD in joint/mixed group 94% vs 40% @RheumNow #EULAR2022 POS1333 https://t.co/FfYBIEGGgJ
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 POS0207
Fatigue in early RA:
⭐️Does not show direct effect between inflammation on fatigue
⭐️Suggests broader indirect effect of psychosocial aspects of wellbeing (pain, mental health, sleep, disease perception) plays larger role
@Rheumnow https://t.co/zTxk7kZRIX
Eric Dein ericdeinmd ( View Tweet)
Szekanecz et al. ORAL Surveillance. Geographic differences in MACE largely driven by history CVD and high baseline risk in North America and ROW. @RheumNow #EULAR2022 POS0110 https://t.co/cR6a7N2KP5
Richard Conway RichardPAConway ( View Tweet)
Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generally stopped due to remission, 10% stopped due to adverse event @RheumNow #EULAR2022 POS0267 https://t.co/jlZDTinfCK
Richard Conway RichardPAConway ( View Tweet)
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
Dr. Antoni Chan synovialjoints ( View Tweet)
For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound?
PsO pts with MSK pain n=79
USS inflamm in 47%
Site-spec correlate only OR 3.1
Even if we act on USS:
PsA Rx is systemic, so overall impression is good enough anyway?
POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw
David Liew drdavidliew ( View Tweet)
Are wearable devices useful in assessing physical activity in rheumatic diseases?
Meta-analysis showed pts with rheumatic diseases reached recommended threshold for moderate to vigorous physical activity but not daily steps.
@RheumNow #EULAR2022 POST#POS0163
Robert B Chao, MD doctorRBC ( View Tweet)
Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw
Richard Conway RichardPAConway ( View Tweet)
OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF
TheDaoIndex KDAO2011 ( View Tweet)
Dougados et al. MACE in tofa clinical programme. Baseline CV risk important. Overall MACE IR 0.38 [0.26-0.54]. MACE IR lower than in ORAL Surveillance in CV enriched pop 0.72 [0.46-1.09]. @RheumNow #EULAR2022 OP0264 https://t.co/lGTTEx0X5p https://t.co/MvD6kjkpse
Links:
Richard Conway RichardPAConway ( View Tweet)